Johnson & Johnson Inc. (JNJ) – Get the report posted stronger-than-expected gains during the fourth quarter on Tuesday and said it will “soon” provide an update on vaccine development progress.
Johnson & Johnson said adjusted earnings for the three months ending December were set at $ 1.86 per share, down 1.1% from the same period last year, but at four cents of consensus forecast on the street. The group’s revenue, according to Johnson & Johnson, rose 8.3% to $ 22.5 billion, again surpassing analysts ’estimates of $ 21.677 billion.
The health brands and consumers group said it saw adjusted profit growth of 16.4% for 2021, or $ 9.40 to $ 9.60 per share, along with growth in sales around 8.8%.
“Our remarkable year-round exercise reflects the continued confidence of patients, physicians, clients and consumers in our life-enhancing products and drugs, especially throughout the COVID-19 pandemic,” said CEO Alex Gorsky.
I am incredibly proud of our Johnson & Johnson teams around the world for overcoming and meeting the needs of stakeholders. These efforts, and our commitment to families around the world as a broad-based healthcare company, allowed us to lead the fight against COVID-19, “he added.” We continue to make progress on our candidate for the COVID-19 vaccine and look forward to sharing details of our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and the years to come. ”
Shares of Johnson & Johnson rose 3.6% more in the first immediate operations after the launch of the hands-on change to $ 171.45 each, extending the six-month earnings of the stock to around 15 %.
Pharmaceutical sales lead the group’s sector gains, up 16.3% from last year to $ 12.27 billion, driven by solid revenues from Stelara treatment for immune-mediated inflammatory diseases and by Imbruvica, his drug against blood cancer.
This helped offset a 0.7% drop in medical device revenue, which reached $ 6.59 billion, and a modest 1.4% gain in consumer health sales of $ 3,600. millions of dollars.